Introduction {#sec1-1}
============

Infertility though not a physically disabling disorder has far reaching psychological and social consequences.\[[@ref1]\] The advent of medical science treatments, especially intra-cytoplasmic sperm injection (ICSI) in the field of assisted reproductive techniques (ART), has been devised to overcome the conditions pertaining to severe male factor infertility, oligoasthenoteratozoospermia (OAT).\[[@ref2]\] The success rates of *in vitro* fertilization (IVF) techniques depend largely on the ovarian response at the time of oocyte retrieval which eventually reflects on the ovarian reserve.\[[@ref3]\] The term "ovarian reserve" describes the number and the quality of the remaining oocytes in the ovaries. Anti-Mullerian hormone (AMH) is a promising marker of ovarian reserve that is produced by the granulosa cells of preantral and antral follicles.\[[@ref4]\] After production, AMH is released into the circulation from the granulosa cells and can be measured in plasma. AMH has the potential to predict future reproductive lifespan and is therefore considered to be the best endocrine marker for assessing age-related decline of ovarian pool in healthy women. Since AMH level is indicative of ovarian response, its measurement becomes an inevitable criteria before IVF.\[[@ref5]\] Considering the high cost and possible complications of ART procedures,\[[@ref6]\] the unavoidable role of AMH as a superior candidate predicting ovarian reserve\[[@ref7][@ref8]\] has been explored in various studies. Therefore, uncertainty in the ART procedure outcome can be minimized to a greater extent. Reports suggest that patients with a diminished ovarian reserve have the only option of IVF with a donor egg.\[[@ref9]\] The clinical symptoms observed in the present case report resembles to *Dhatukshayajanya Vandhyata* (infertility due to depletion of body tissues), that has been already explained in Ayurveda. The role of an effective Ayurvedic treatment protocol to improve the AMH level to a satisfactory level to have a better response to ovarian stimulation for IVF has to be validated, thereby opening a scope of an integrated medical approach. The present case report is an attempt on the same.

Case Report {#sec1-2}
===========

Presenting concerns {#sec2-1}
-------------------

The case of this report is a 36-year-old married, nonsmoking, non-alcoholic female with primary infertility since 9 years of married life undergoing continuous interventions and repeated ART. Previous specialized evaluations include hormonal assays such as follicle-stimulating hormone, luteinizing hormone, estradiol, thyroid function test and AMH; ultrasonography (USG); and karyotyping. Investigations into the male factor revealed OAT. She underwent three courses of intrauterine insemination (IUI) and three courses of ICSI which were unsuccessful. AMH value before fourth ICSI was very low after which she was advised for an ICSI with a donor ovum.

Clinical findings {#sec2-2}
-----------------

The patient got married in the year 2005 at the age of 27 years. Investigations carried out on both partners after 2 years of married life revealed OAT. After correcting the sperm count with oral medications, she underwent three cycles of IUI in 2010 which was unsuccessful. Due to OAT and failed IUIs, she was subjected for ICSI after necessary hematological evaluation and hormonal assays which came out to be normal. AMH value was 2.5 ng/mL before first ICSI on November 3, 2011. Six eggs were retrieved and one embryo was transferred, but there was no rise in human chorionic gonadotropin (hCG) value. Second ICSI was on May 10, 2012, in which three eggs were retrieved and three matured embryos were transferred. hCG value raised to \>1500 mIU/ml on May 31, 2012, but had tubal abortion on June 3, 2012. Third ICSI was on July 21, 2013 and three embryos were transferred from five retrieved eggs. She had threatened abortion on August 19, 2013, and USG on August 20, 2013, showed single intrauterine gestational sac with subchorionic hematoma and a repeated scan on September 3, 2013, revealed an empty endometrial cavity. Routine investigations carried out on January 2, 2014, before fourth ICSI revealed very low AMH value (0.07 ng/mL). She was advised for undergoing next ICSI with a donor ovum due to the low AMH value. As the couple was not willing to accept a donor egg, they visited our outpatient department (OPD) on February 1, 2014 in the hope of undergoing ICSI with her own ova by improving the AMH value with Ayurvedic treatment. Her medication includes Eltroxin 50 mcg for hypothyroidism since 2010. Her history was relevant only for chickenpox in 2005 and jaundice in 2012. Family history was negative for any premature ovarian failure or low AMH. Her personal history revealed a regular bowel habit and sound sleep. Her appetite was apparently normal and the tongue was uncoated. She attained menarche at the age of 12 years with 2--3 days' duration in 26--28 days' interval. The amount was scanty with noticeable vaginal dryness since 3 months. Her obstetric history was gravida 2 abortion 2 ectopic pregnancy 1 (G2A2E1). On examination, she was calm and pain free. Her blood pressure was 120/80 mmHg, pulse rate 70/min and body mass index 23 kg/m^2^. She is of *Vata Kapha Prakṛiti* with *Madhyama Satva* (moderate mental strength) and *Madhyama Koshtha* (moderate bowel). Her physical examination and examination of external genitalia did not revealed any abnormal findings. Per speculum examination showed a healthy nulliparous cervix without any significant abnormality. Bimanual examination revealed an anteverted mobile uterus with a negative cervical motion tenderness. Medical history of the patient is detailed in [Table 1](#T1){ref-type="table"}.

###### 

Timeline of medical history
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Diagnostic focus and assessment {#sec2-3}
-------------------------------

In the view of symptoms of *Artava Kshaya* (hypomenorrhea), the present case was diagnosed as *Dhatukshayajanya Vandhyata* (infertility due to depletion of body tissues). The assessment was done by comparing baseline AMH value with repeated evaluation after 3 months of *Shamana* (oral medication) and *Shodhana* treatment (purification therapy). Baseline AMH value was 0.07 ng/ml (reference range: 2--6.80).

Therapeutic focus and assessment {#sec2-4}
--------------------------------

The therapeutic plan was to administer *Shamana Chikitsa* (oral medication) followed by *Shodhana Chikitsa* (purification therapy). *Shamana Chikitsa* was done for 3 months with *Vaishavanara Churna* and *Mahanarayana Taila*. As her clinical symptoms and AMH value after *Samana Chikitsa* showed satisfactory improvement, she was subjected to *Shodhana Chikitsa*. Initially, her *Agni* was corrected by *Dipana-Pachana* (improving digestion) with *Vaishavanara Churna* as a *Purvakarma* (preparation) of *Shodhana*. She attained *Nirama Lakshana* (signs of digestion of *Ama*) by 2 days after which *Accha Snehapana* (intake of oil) was started with *Mahanarayana Taila*. *Samyak Snigdha Laksana* (signs of proper oleation) was observed after 6 days of *Snehapāna*. *Mridu Virechana* (mild purgation) was performed on the administration of *Trivritlehya*. After *Virechana*, she was subjected to *Yoga Basti* and *Uttara Basti* (medicated enema). After completion of *Shodhana* therapy, she was discharged from the hospital \[[Table 2](#T2){ref-type="table"}\].

###### 

Treatment protocol
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Follow-up and outcomes {#sec2-5}
----------------------

After 3 months, the patient was advised to have a follow-up in the OPD with a reassessment of AMH value. It was observed that there was a marked improvement in the AMH value as shown in [Table 3](#T3){ref-type="table"}.

###### 

Results of baseline and follow-up assessment of anti-Mullerian hormone value
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Discussion {#sec1-3}
==========

The psychosocial stigma related to infertility has provoked the need for an ART in spite of the time-consuming, expensive, and stressful strategies. ICSI has now created a new opening in the treatment of previously untreated cases of severe male factor infertility. The value of AMH in detecting the ovarian reserve for an IVF cycle has begun to be better understood in the recent years. It is so unfortunate that donor egg IVF would be the last option of them who have a low AMH value with poor ovarian reserve. Lack of awareness regarding the efficacy of an integrated approach to medical intervention in such cases to proceed with a donor egg IVF technique has grown up as a great challenge to the physicians as well as patients. To satisfy the needs of the present situation, there should be a better understanding regarding the importance of *Garbha Samagri*\[[@ref10]\] (essential elements for healthy conception), thereby generating better treatment options. Although the Ayurvedic approach to *Dhatukshayajanya Vandhyata*\[[@ref11]\] in terms of low level of AMH is gaining importance, the lacuna of effective research works based on the integrated medical approach still exists. The present disease entity with a close resemblance to *Dhatukshayajanya Vandhyata* can be traced out as an attributing female factor in association with the male factor for infertility. The case presents with a *Vata Dosha Vikriti* (alteration of *Dosha)* progressing toward a *Dhatu kṣhaya*, thereby affecting *Artava Upadhatu* which was evident from the *Artavakshaya Lakshana*\[[@ref12]\] of the patient. The treatment protocol aims for a *Shamana* of *Vata Dosha* and correction of *Agni*, thereby creating equilibrium of *Doshas* in the *Madhyama Vaya* (middle age) *Avastha*. The *Dhatu Pushti* itself can be attributed for the physiology of *Artava*. Oral administration of *Vaishvanara Churna*\[[@ref13]\] having *Dipana* and *Pachana* properties helps in *Agni Vardhana* (enhancing digestive fire), which in turn corrects *Dhatu Parinama* (transformation of *Dhatu*). Oral administration of *Mahanarayana Taila*\[[@ref14]\] owing to its *Vatahara*, *Dhatuvardhaka*, *Vandhyatvahari*, *Balya* and *Brimhana* properties helps in the improvement of *Artavaksaya* through *Dhatupusti*, thus creating a satisfactory improvement in the AMH value. Furthermore, *Mahanarayana Taila* used for *Snehapana* imparts a synergistic effect on *Dhatu Pushti*. *Virechana* helps in attaining *Agni Dipti* and *Sroto Vishuddhi* (purification of channels) and hence supports the proper *Dha*t*u Parinama*.\[[@ref15]\]

Pathogenesis of gynecological disorders always involves *Vata Dosha*.\[[@ref16]\] Hence, *Basti Karma*, which is the best therapy for *Vata Shamana*, was administered after *Mrdu Shodhana*. In Ayurveda, *Mustadiyapana Basti*\[[@ref17]\] is indicated for infertility as it is *Balajanana*. *Uttara Basti* is indicated for all gynecological disorders, especially in *Puspanasa* (destruction of ovum).\[[@ref18]\] Notable improvement in the symptoms of *Artavaksaya* (scanty menstruation and vaginal dryness) was observed after the *Shodhana Karma*. The value of AMH after the treatment was considerably improved on a much satisfactory level, so that the option of egg donation IVF could be discarded.

Conclusion {#sec1-4}
==========

This Ayurvedic treatment protocol including a combination of both *Shamana* and *Shodhana* therapies were helpful in improving the AMH value to a satisfactory level. Hence, this was helpful for the patient to undergo an IVF treatment with her own eggs that was not possible earlier due to low AMH level. Therefore, this approach can be considered in patients with low AMH values and for further research in integrative medicine.

Patient perspective {#sec2-6}
-------------------

The patient was satisfied with the treatment as she had considerable improvement in the AMH value that made her eligible for an ICSI with her own ovum.

Patient consent {#sec2-7}
---------------

The patient provided written permission for publication of this case report.
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